Home/Dobrinka Encheva

About Dobrinka Encheva

This author has not yet filled in any details.
So far Dobrinka Encheva has created 57 blog entries.

Ophthalmic device co EyeYon Medical raises $6.5m

21 Mar, 2017 13:53 Globes correspondent China-based venture capital fund Rimonci Capital and co-investor Gauss Group led the financing round. Israeli ophthalmic device co EyeYon Medical founded by ophthalmologists Dr. Arie Marcovich and Dr. Daphna Ofer, and managed by CEO Nahum Ferera, has raised $6.5 million. The company, which emerged from the Val Leer incubator, [...]

By | 2017-03-22T09:30:00+00:00 March 22nd, 2017|Blog|0 Comments

IBM Watson Health To Integrate MedyMatch Technology Into Cognitive Imaging Offerings To Help Doctors Identify Head Trauma And Stroke

MedyMatch Application to Help Doctors Identify Head Trauma and Stroke MedyMatch Technology recently announced a collaboration with IBM Watson Health to bring MedyMatch’s A.I.-based clinical decision support application to imaging experts working in hospital emergency rooms and other acute care settings to help doctors identify instances of intracranial bleeding as a result of head trauma [...]

By | 2017-03-22T09:25:36+00:00 March 22nd, 2017|Blog|0 Comments

Mixiii Biomed 2017 Preliminary Program

  PRELIMINARY PROGRAM MIXiii Biomed 2017 - The time for Israel International Innovation is Now! CONFERENCE TRACKS The moment we have all been waiting for is finally here. MIXiii Biomed 2017 is officially opening its doors, offering you a most unique conference experience.The Preliminary Conference Program is now online for you to View with ten main tracks [...]

By | 2017-03-23T11:43:58+00:00 March 20th, 2017|Blog|0 Comments

Intermountain taps Zebra Medical Vision to apply deep learning to medical imaging

Imaging analytics promise to change the practice of radiology, an Intermountain official says. By Bernie Monegain March 16, 2017 Intermountain Healthcare is working with Zebra Medical Vision, a deep learning imaging analytics company, based in Israel to integrate machine learning in medical imaging analysis. The goal is to provide better patient care. Here’s how it [...]

By | 2017-03-19T12:16:20+00:00 March 19th, 2017|Blog|0 Comments

MIXIII BIOMED 2017: Call for Company presentations

  Call for Abstracts / Oral Company Presentations This is your Chance to take the Stage and Speak at Mixiii Biomed 2017!!! Don't miss this opportunity to participate- Submission Deadline is April 10, 2017! We hereby invite you to take an Active Role by submitting a Company Presentation Abstract to one of the track categories in the MIXiii Biomed [...]

By | 2017-03-19T10:57:05+00:00 March 19th, 2017|Blog|0 Comments

FDA fast tracks Israeli co PolyPid

PolyPid is developing a localized delayed release antibiotic for treatment of bone infections. Israeli company PolyPid Optimized Therapeutics, which is developing a localized delayed release antibiotic for treatment of bone infections, has announced its acceptance to the US Food and Drug Administration (FDA) Qualified Infectious Disease Program (QIDP). QIDP is a fairly new FDA status [...]

By | 2017-03-16T11:20:07+00:00 March 15th, 2017|Blog|0 Comments

Inside Israel: The Start-Up Nation Looks East For Investment

06 Mar 2017 ANALYSIS Catherine Longworth@MedtechCate Health IT is set to be one of the subjects explored at the MIXiii BIOMED annual conference, Israel's leading international life science industry conference. The conference, now in its 16th year, will be held in Tel Aviv in May and is expected to attract over 6,000 participants. This year [...]

By | 2017-03-08T07:42:46+00:00 March 8th, 2017|Blog|0 Comments

Cnoga Medical raises $50m from China’s BOE

 6 Mar, 2017 Gali Weinreb Cnoga's non-invasive devices measure health through optical diagnosis of the changing color shades of a finger. Chinese company BOE has invested $50 million in Israeli company Cnoga Medical for 23% of the company's shares, reflecting a company value of $217 million, the two companies today reported. The shares given to [...]

By | 2017-03-07T12:20:15+00:00 March 7th, 2017|Blog|0 Comments

NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson’s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting

- Trial 006 demonstrated a statistically significant and clinically meaningful reduction in OFF-time and increase in proportion of patients “ON” by 8:00 am (primary and key secondary endpoints) - - The trial also showed statistically significant reduction in troublesome dyskinesia and a complete reduction of OFF-time to zero hours in 66% of responders (post hoc [...]

By | 2017-03-06T08:23:52+00:00 March 6th, 2017|Blog|0 Comments

Gamida #Cell Announces First Patient #Transplanted in Phase 3 Registration Study of NiCord for #Blood #Cancers

JERUSALEM, Feb. 28, 2017 /PRNewswire/ -- Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that the first patient has been transplanted in the Company's Phase 3 study of NiCord®, in development as a cure for patients with blood cancer who do not have [...]

By | 2017-03-06T08:19:39+00:00 March 6th, 2017|Blog|0 Comments